Press Releases HBM Holdings Limited

Equities

2142

KYG4403H1002

Market Closed - Hong Kong S.E. Other stock markets 01:38:22 10/05/2024 pm IST			5-day change	1st Jan Change
1.47 ^HKD	-4.55%		+13.95%	-24.23%

02/04	HBM Holdings Returns to Profitability in 2023	MT
28/03	HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Harbour BioMed Reports Full Year 2023 Financial Results	28/03	PR
Harbour BioMed Announces Positive Profit Alert	19/01	PR
Harbour BioMed's Wholly-owned Subsidiary Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate	15/12	AQ
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director	08/23/08	PR
Harbour BioMed Announces 2023 Interim Results Positive Profit Alert with the Enhancement of Value Driven by Innovation	13/23/13	PR
Nona Biosciences Enters into Antibody Discovery Agreement with OPKO Health's ModeX Therapeutics	24/23/24	AQ
Harbour BioMed Reports Full Year 2022 Financial Results	03/23/03	PR
Nona Biosciences Enters into HCAb Based Antibody Discovery Collaboration Agreement with Mythic Therapeutics	13/23/13	AQ
HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders	26/23/26	PR
Nona Biosciences Enters into HCAb Based Drug Discovery Collaboration Agreement with Dragonfly Therapeutics	21/22/21	AQ
Harbour BioMed Enters into a License and Collaboration Agreement with Moderna	11/22/11	PR
MISSISSIPPI LIME COMPANY DRIVES GLOBAL EXPANSION WITH THE ACQUISITION OF SINGLETON BIRCH	08/22/08	AQ
Harbour BioMed Appoints Dr. Alexander A. Zukiwski to its Scientific Advisory Board	06/22/06	PR
Harbour BioMed Announces Global Out-License Agreement with AstraZeneca for CLDN18.2xCD3 Bispecific Antibody HBM7022	07/22/07	PR
Harbour BioMed Reports Full Year 2021 Financial Results: Empower Value Creation with Global Innovation Capabilities	25/22/25	PR
Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003	04/22/04	PR
Harbour BioMed : Announces NMPA Approval of Two IND Applications for Next-Generation Anti-CTLA-4 Antibody HBM4003	14/21/14	PR
HBM : VOLUNTARY ANNOUNCEMENT - DOSING OF FIRST PATIENT IN PHASE Ib/IIa CLINICAL STUDY OF NEXT-GENERATION ANTI-CTLA-4 ANTIBODY IN AUSTRALIA	12/21/12	PU
HBM : PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; RE-ELECTION OF RETIRING DIRECTORS; AND NOTICE OF ANNUAL GENERAL MEETING	28/21/28	PU
HBM : LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS	26/21/26	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases HBM Holdings Limited

Equities

2142

KYG4403H1002

Press Releases

Filters